ArticleJournal of advanced veterinary and animal research2022
Preliminary study on designing the binder of sperm-1 synthetic vaccine using sequence-based methods and molecular docking.
Article in Journal of advanced veterinary and animal research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The main objective of this study is to design a synthetic vaccine from the binder of sperm-1 (BSP1). Materials and Methods: This study was carried out using bioinformatics-related techniques. BSP-1 has been chosen as one of the biomarkers of a ruminant's male fertility. We hypothesize that the BSP1 synthetic vaccines, which contain T-cell epitopes, can produce antibodies more effectively for the development of a sperm fertility detection kit. A sequence of BSP-1 peptides A0A0K1YXR5 from Results: In this study, we succeeded in making synthetic vaccines from BSP-1 with a peptide sequence of LPEDSVPDEERVFPFTYRNRKHF. The three-dimensional theoretical prediction analysis of the peptide binding pattern to its ligand, as well as the molecular docking, has also been revealed. Conclusions: A synthetic vaccine from the BSP-1 has been developed in this study with the amino acid sequence LPEDSVPDEERVFPFTYRNRKHF, which is buffer-soluble, and the three-dimensional theoretical prediction analysis of the peptide binding pattern of BSP-1 to its ligand, as well as molecular docking, has also been revealed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.